Danaher entered a definitive agreement to acquire Masimo Corporation for approximately $9.9 billion ($180 per share), accelerating Danaher’s push into acute‑care monitoring and diagnostics. The transaction brings Masimo’s pulse oximetry and patient‑monitoring portfolio under Danaher’s Diagnostics segment and signals further consolidation in bedside monitoring and device integration. Danaher framed the deal as expanding access to continuous clinical data inside hospitals and complementing its diagnostic workflows. Industry observers view the acquisition as part of a broader strategy by large industrial health companies to assemble vertically integrated diagnostic and monitoring platforms.